Felbamate, Serum or Plasma

CPT: 80339
Print Share

Test Details


  • Felbatol®


Evaluate toxicity; monitor therapeutic levels


Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Reference Interval

Therapeutic: 25−104 μg/mL; steady-state trough levels are dose proportional in adults. Multiple daily doses of 1200, 2400, and 3600 mg/day gave trough levels of 25−35, 47−63, and 62−104 μg/mL, respectively. Steady-state peak concentrations are dose proportional in children ages 4 to 12 years over a range of 15, 30, 45 mg/kg/day. The dose proportional peak concentrations were reported as 17, 32, and 49 μg/mL, respectively at two to six hours postdose. Co-administration of carbamazepine, phenytoin, phenobarbital, or primidone can cause a decrease in felbamate plasma concentrations; conversely, valproic acid can increase concentrations.1 In children, a similar effect was found with carbamazepine and phenytoin decreasing levels and an opposite effect with valproic acid.2

Additional Information

Following oral administration, felbamate is 25% bound to serum albumin. Approximately 40% to 50% of the absorbed dose appears unchanged in the urine. The rest is present as nonactive metabolites, including parahydroxyfelbamate, 2-hydroxyfelbamate, and felbamate monocarbamate. Felbamate has an elimination half-life of 20 to 23 hours. The apparent volume of distribution is 0.7−1.0 L/kg.

Specimen Requirements


Serum or plasma


2 mL

Minimum Volume

0.6 mL


Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.


Transfer separated serum or plasma to a plastic transport tube.

Storage Instructions

Room temperature

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Gel-barrier tube

Clinical Information


1. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: What improvements are needed? Neurology. 2000; 55(Suppl 3):S11-S16. 11147563
2. Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit. 1997 Feb; 19(1):29-36. 9029743


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
716530 Felbamate (Felbatol(R)), Serum 6899-9 716531 Felbamate, Serum ug/mL 6899-9

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf